One hundred percent
Rospotrebnadzor declared 100% immunological efficacy of Epivaccorona
According to the results of the first two phases of clinical trials, the immunological effectiveness of the Epivaccorona coronavirus vaccine developed by the Vector State Scientific Center for Virology and Biotechnology is 100%. This was reported to journalists on Tuesday in the press service of Rospotrebnadzor.
"The effectiveness of the vaccine consists of its immunological effectiveness and preventive effectiveness. According to the results of the first and second phases of clinical trials, the immunological effectiveness of the Epivaccorona vaccine is 100%," the report says.
On July 24, the Vector Center received permission from the Ministry of Health of the Russian Federation to conduct clinical trials of the vaccine on volunteers. They ended on September 30. On October 14, Russian President Vladimir Putin announced that the vaccine of the Vector Center had received a registration certificate. On November 16, the Ministry of Health of the Russian Federation granted the center permission to conduct post-registration studies of the Epivaccorona vaccine on volunteers over 60 years of age on 150 volunteers and on November 18 – for tests on 3 thousand volunteers.
Portal "Eternal youth" http://vechnayamolodost.ru